BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BONCRESA (denosumab-mobz) by Amneal Pharms is rank ligand blocking activity [moa]. First approved in 2025.
Drug data last refreshed 18h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BONCRESA (denosumab-mobz) is a monoclonal antibody that blocks RANK ligand to inhibit osteoclast formation and bone resorption. It is a biosimilar referencing the original denosumab molecule for subcutaneous injection. Indications for this product are not yet specified in available data.
Launch
Early-stage biosimilar launch with moderate competitive pressure (30/100); team building and market penetration strategy will be critical priorities.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BONCRESA offers exposure to biosimilar commercialization strategy, managed care negotiation, and competitive positioning in a crowded market. This role suits professionals interested in access, pricing strategy, and launch execution rather than drug discovery or clinical development.
Brand ManagerMarket Access Manager
Worked on BONCRESA at Amneal Pharms? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.